ZyVersa CEO says ‘deeply committed’ to executing with discipline, urgency

CEO Stephen Glover said, in part, “Over my 40-year career, I’ve seen the full arc of biotech-celebrated successes and weathered setbacks. Today’s biotech environment ranks among the most challenging we’ve faced: capital markets remain tight, sector valuations are compressed, major exchanges are underperforming, and investor sentiment is cautious. Yet history teaches us that it’s in these moments-when others pull back-that focused, disciplined companies with sound science and strong leadership can chart a breakthrough course. At ZyVersa, we believe we are exceptionally positioned to do just that. Our pipeline is advancing. Our science is differentiated. Our mission-to deliver transformative therapies for patients with serious unmet needs-has never been more urgent. But to realize this potential, your continued support is essential. We remain deeply committed to executing with discipline and urgency. In a market that rewards resilience, ZyVersa is staying the course-with focus, strategic clarity, and resolve. Together, we can build long-term value for patients, the healthcare system, and our shareholders. I am pleased to announce that in Q2-2025, we closed two financing transactions providing access to $12 million in capital to advance our R&D initiatives. On July 8, 2025, we closed a $2M warrant inducement transaction from a current investor, and on June 25, 2025, we closed a Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings. This increased capital supports advancement of our key development programs targeting kidney and inflammatory diseases to value-building inflection points over the next several months…In closing, we call on you, our shareholders, to: Support your investment with your belief that new innovative medicines make a difference for patients and society. Recognize the opportunity for long-term value creation as we execute in a market where disciplined, science-driven companies will emerge stronger. Stand with management and the Board as we make bold, necessary decisions to weather near-term pressures and drive toward key inflection points over the next six months. The Bottom Line: In a cautious market, conviction matters. ZyVersa is committed to building breakthrough value in kidney and inflammatory diseases, grounded in rigorous science and strategic execution. We thank you for your continued trust and partnership. With your support, we can seize this moment-transforming patient outcomes while delivering long-term value for shareholders.”